Lineage Cell Therapeutics (NYSE: LCTX) revenue
Lineage Cell Therapeutics reported revenue of $14.6m for fiscal 2025, 53.2% more than in fiscal 2024 ($9.5m). Since fiscal 2016 its revenue has grown by 145.8%, an average growth of 10.5% a year.
Lineage Cell Therapeutics has grown its revenue for 2 years in a row, and its best year of the last 10 was fiscal 2022. The biggest drop was in fiscal 2020, −48.1%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $14.6m | +53.2% | −$36.6m | −251.6% |
| 2024 | $9.5m | +6.2% | −$21.5m | −226.1% |
| 2023 | $8.9m | −39.2% | −$24.7m | −276.5% |
| 2022 | $14.7m | +238.7% | −$22.5m | −153.2% |
| 2021 | $4.3m | +137.7% | −$49.2m | −1,133.6% |
| 2020 | $1.8m | −48.1% | −$26.4m | −1,448.4% |
| 2019 | $3.5m | −29.5% | −$38.9m | −1,106.0% |
| 2018 | $5.0m | +44.2% | −$41.8m | −837.9% |
| 2017 | $3.5m | −41.6% | −$38.9m | −1,125.0% |
| 2016 | $5.9m | — | −$59.0m | −995.6% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Lineage Cell Therapeutics revenue compared with its sector
By revenue for its latest fiscal year, Lineage Cell Therapeutics ranks 359th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Lineage Cell Therapeutics, 53.2%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 357th | Dianthus Therapeutics | $16.1m | −7.2% |
| 358th | Relay Therapeutics | $15.4m | 53.4% |
| 359th | Lineage Cell Therapeutics | $14.6m | 53.2% |
| 360th | Opus Genetics | $14.2m | 29.1% |
| 361st | Arbutus Biopharma | $14.1m | 128.2% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Lineage Cell Therapeutics
- How much revenue did Lineage Cell Therapeutics make in fiscal 2025?
- Lineage Cell Therapeutics reported revenue of $14.6m for fiscal 2025, compared with $9.5m in fiscal 2024.
- How much has the revenue of Lineage Cell Therapeutics grown?
- Between fiscal 2016 and fiscal 2025 it went from $5.9m to $14.6m: 145.8% more, an average growth of 10.5% a year.
- What was the best year for revenue at Lineage Cell Therapeutics?
- Of its last 10 fiscal years, fiscal 2022, with $14.7m.
- Where does Lineage Cell Therapeutics rank in its sector by revenue?
- It ranks 359th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Lineage Cell Therapeutics come from?
- From the annual report (Form 10-K) that Lineage Cell Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Lineage Cell Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Lineage Cell Therapeutics: the Lineage Cell Therapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.